{"schema_version":"secwatch.filing_event.v1","accession":"0001703057-25-000024","form_type":"8-K","ticker":"ABCL","cik":"0001703057","company_name":"AbCellera Biologics Inc.","filed_at":"2025-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.198571+00:00","generated_at":"2026-05-16T23:48:30.786972+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"AbCellera Q3 net loss widens to $57.1M; revenue rises to $9.0M","bullets":["Net loss of $57.1M ($0.19/share) vs $51.1M ($0.17/share) in Q3 2024.","Total revenue $9.0M, up from $6.5M in Q3 2024.","Appointed Sarah Noonberg, M.D., Ph.D., as Chief Medical Officer.","Cumulative partner-initiated program starts with downstreams: 103; molecules in clinic: 18.","Total available liquidity $680M ($523M cash/securities + $159M non-dilutive funding)."],"urls":{"canonical":"https://secwatch.observer/filing/0001703057-25-000024","json":"https://secwatch.observer/filing/0001703057-25-000024.json","markdown":"https://secwatch.observer/filing/0001703057-25-000024.md","text":"https://secwatch.observer/filing/0001703057-25-000024.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1703057/000170305725000024/0001703057-25-000024-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1703057/000170305725000024/abcl-20251106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T23:48:30.786972+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}